A law signed in 2023 caps out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors beginning Jan. 1.

Clinical programs for inhaled insulin have received several setbacks of late, with Bagsværd, Denmark-based Novo Nordisk deciding in January to terminate phase 3 trials of its inhaler and ...

A brand new law will bring financial relief to hundreds of thousands of Minnesotans dealing with diabetes and asthma. The law ...

The pharmacokinetic profile of inhaled insulin has both advantages and disadvantages compared with subcutaneous insulin injection. Because inhaled insulin is more quickly absorbed, pulmonary ...

A new Minnesota law that caps the price of some live-saving prescription drugs goes into effect on Jan. 1, 2025, which could ...

“Afrezza is a rapid-acting insulin delivered through an inhaler as compared to current insulins which are given as injections. Taken at the beginning of a meal, Afrezza dissolves rapidly upon ...

“We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.” MannKind ...

MNKD’s portfolio in the endocrine area includes Afrezza, an insulin human inhalation powder for adults with diabetes mellitus type 2 [T2D]. Currently, Afrezza is marketed in the US and ...

For adults with type 1 diabetes, a regimen of inhaled Technosphere insulin (TI) plus insulin degludec is noninferior to usual care for glycemic control, according to a study published online Dec ...

An “inhaled insulin” is set to join the repertoire of options available to people with diabetes, as drugmaker Cipla completes last mile procedures to import Afrezza from US’ MannKind ...